Efficacy of a tailored approach with nivolumab (N) and nivolumab plus ipilimumab (N plus I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC

被引：0
|
作者：
Grimm, M-O. [1 ]
Schostak, M. [2 ]
Gruen, C. B. [3 ]
Loidl, W. C. [4 ]
Pichler, M. [5 ]
Zimmermann, U. [6 ]
Schmitz-Draeger, B. J. [7 ]
Steiner, T. [8 ]
Roghmann, F. [9 ]
Niegisch, G. [10 ]
Schmitz, M. [11 ]
Baretton, G. [12 ]
Leucht, K. [1 ]
Schumacher, U. [13 ]
Foller, S. [14 ]
Zengerling, F. [15 ]
Meran, J. [16 ]
机构：
[1] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[2] Magdeburg Univ Hosp, Dept Urol, Magdeburg, Germany
[3] Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[4] Elisabethinen Hosp, Dept Urol, Linz, Austria
[5] Graz Univ Hosp, Dept Oncol, Graz, Austria
[6] Greifswald Univ Hosp, Dept Urol, Greifswald, Germany
[7] St Theresien Krankenhaus, Urol 24, Nurnberg, Germany
[8] Helios Hosp Erfurt, Dept Urol, Erfurt, Germany
[9] Univ Hosp Ruhr Univ Bochum, Marien Hosp Herne, Dept Urol, Herne, Germany
[10] Heinrich Heine Univ Dusseldorf, Dusseldorf Univ Hosp, Dept Urol, Dusseldorf, Germany
[11] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Immunol, Dresden, Germany
[12] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Pathol, Dresden, Germany
[13] Friedrich Schiller Univ Jena, Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[14] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Urol, Jena, Germany
[15] Ulm Univ Hosp, Dept Urol, Ulm, Germany
[16] Hosp Barmherzige Brueder, Dept Internal Med Hematol & Internal Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2372P
引用
收藏
页码：S1207 / S1208
页数：2
相关论文
共 50 条
  • [21] Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
    Jain, Rohit K.
    Yang, Yuanquan
    Chadha, Juskaran
    Chatwal, Monica Sheila
    Kish, Julie Ann
    Raymond, Sarah
    Rembisz, Jennifer
    Jameel, Ghazal
    Mustasam, Arfa
    Poehlman, Trey
    Fan, Wenyi
    Kim, Youngchul
    Dhillon, Jasreman
    Alemany, Carlos A.
    Mortazavi, Amir
    Zhang, Jingsong
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [22] Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis)
    Thana, Myuran
    Basappa, Naveen S.
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Graham, Jeffrey
    Soulieres, Denis
    Hansen, Aaron Richard
    Lalani, Aly-Khan A.
    Castonguay, Vincent
    Reaume, M. Neil
    Bjarnason, Georg A.
    Breau, Rodney H.
    Pouliot, Frederic
    Kapoor, Anil
    Wood, Lori
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
    Apolo, A. B.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Francis, D. C.
    Cordes, L. M.
    Berniger, M.
    Steinberg, S. M.
    Monk, P.
    Lancaster, T.
    Mayer, T.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
    Sharma, P.
    Siefker-Radtke, A. O.
    de Braud, F.
    Basso, U.
    Calvo, E.
    Bono, P.
    Morse, M.
    Ascierto, P. A.
    Lopez-Martin, J.
    Brossart, P.
    Rohrberg, K. S.
    Mellado, B.
    Li, S.
    Baudelet, C.
    Unsal-Kacmaz, K.
    Callahan, M. K.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2020, 31 : S582 - S583
  • [25] Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab plus ipilimumab (N plus I): A real-world study
    Geldart, T. R.
    Pickering, L. M.
    Sharma, A.
    Scott, D.
    Parikh, O. A.
    Coleman, S.
    Dhokia, P.
    Hale, M.
    Vaz, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1020 - S1020
  • [26] Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
    Jain, R. K.
    Chahoud, J.
    Chatwal, M.
    Kim, Y.
    Dhillon, J.
    Vosoughi, A.
    Araujo, C.
    Li, R.
    Zhang, J.
    Sonpavde, G. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S724 - S724
  • [27] A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
    Apolo, Andrea B.
    Mortazavi, Amir
    Stein, Mark N.
    Davarpanah, Nicole N.
    Nadal, Rosa Maria
    Parnes, Howard L.
    Ning, Yangmin M.
    Francis, Deneise C.
    Cordes, Lisa M.
    Berniger, Marilise Anne
    Steinberg, Seth M.
    Agarwal, Piyush K.
    Bagheri, Mohammadhadi H.
    Nanda, Swati
    Monk, Paul
    Lancaster, Tiffany
    Moore, Tina
    Costello, Rene
    Bottaro, Donald P.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place.
    Meerveld-Eggink, Aafke
    Graafland, Niels
    Wilgenhof, Sofie
    Van Thienen, Johannes V.
    Grant, Michael
    Szabados, Bernadett
    Abu-Ghanem, Yasmin
    Boleti, Ekaterini
    Blank, Christian U.
    Haanen, John B. A. G.
    Powles, Thomas
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Characterization of response to nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
    Rini, B. I.
    Tannir, N. M.
    Escudier, B.
    McDermott, D. F.
    Grimm, M-O.
    Porta, C.
    Powles, T.
    Kollmannsberger, C. K.
    Gurney, H. P.
    Tykodi, S. S.
    Harrison, M.
    Heng, D. Y. C.
    Gruenwald, V.
    Choueiri, T. K.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    George, S.
    ANNALS OF ONCOLOGY, 2018, 29
12345